Donor selection, graft engineering, and dosing oh my!

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Allogeneic hematopoietic cell transplantation offers a curative potential for various malignant and nonmalignant hematologic disorders.
• Optimal donor selection is a critical determinant of transplant success.

Purpose of the Study:

• To review current strategies for selecting the optimal donor in allogeneic hematopoietic cell transplantation.
• To discuss advancements in graft engineering and cell dose optimization to improve patient outcomes.

Main Methods:

• Review of established and emerging donor sources including matched siblings, unrelated donors, haploidentical donors, and umbilical cord blood.
• Exploration of non-human leukocyte antigen factors impacting donor selection, such as donor age and cytomegalovirus status.
• Analysis of graft engineering techniques like T-cell depletion and umbilical cord blood expansion.

Main Results:

• Matched sibling and unrelated donors provide comparable outcomes.
• Haploidentical donors and umbilical cord blood are viable alternative donor sources.
• Graft engineering strategies and cell dose optimization significantly enhance transplant efficacy.

Conclusions:

• A comprehensive approach considering human leukocyte antigen compatibility, non-human leukocyte antigen factors, and advanced graft engineering enables successful donor selection for most patients.
• Continued innovation in transplantation methodologies is leading to improved outcomes for a wider patient population.